Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Cholangiocarcinoma

ClinicalTrials.gov lists 819 trials for Cholangiocarcinoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 23.

MeSH D018281 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 114 Phase 1/2 Phase 1/2 55 Phase 2 Phase 2 268 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 37 Phase 4 Phase 4 12 Not applicable Not applicable 141 Observational Observational 169 Phase 1 Phase 1 114 Phase 1/2 Phase 1/2 55 Phase 2 Phase 2 268 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 37 Phase 4 Phase 4 12 Not applicable Not applicable 141 Observational Observational 169

Trials per phase (log scale)

1 more section with rows

774 of the 819 trials are tagged with Cholangiocarcinoma itself; the rest are tagged with a narrower condition beneath it.

Get the Cholangiocarcinoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Cholangiocarcinoma trials start? (26)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 92

2001: 1 trials (Phase 1/2 1) 2002: 3 trials (Phase 2 3) 2003: 2 trials (Not applicable 1, Phase 1 1) 2004: 6 trials (Observational 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2005: 3 trials (Observational 2, Phase 4 1) 2006: 6 trials (Observational 3, Not applicable 1, Phase 2 2) 2007: 8 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 2 2, Phase 1 3) 2008: 12 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2009: 13 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 2) 2010: 10 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 6) 2011: 19 trials (Observational 5, Not applicable 4, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 2) 2012: 21 trials (Observational 3, Not applicable 6, Phase 2/3 3, Phase 2 4, Phase 1/2 2, Phase 1 3) 2013: 21 trials (Observational 7, Not applicable 4, Phase 4 1, Phase 2 5, Phase 1/2 1, Phase 1 3) 2014: 32 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 9, Phase 1/2 4, Phase 1 4) 2015: 30 trials (Observational 6, Not applicable 6, Phase 3 3, Phase 2 11, Phase 1/2 2, Phase 1 2) 2016: 27 trials (Observational 5, Not applicable 9, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1 6) 2017: 45 trials (Observational 9, Not applicable 9, Phase 3 3, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 10) 2018: 48 trials (Observational 11, Not applicable 6, Phase 3 2, Phase 2/3 1, Phase 2 18, Phase 1/2 6, Phase 1 4) 2019: 45 trials (Observational 3, Not applicable 8, Phase 3 6, Phase 2/3 1, Phase 2 15, Phase 1/2 4, Phase 1 8) 2020: 63 trials (Observational 13, Not applicable 14, Phase 3 1, Phase 2 22, Phase 1/2 4, Phase 1 9) 2021: 60 trials (Observational 12, Not applicable 10, Phase 3 1, Phase 2/3 1, Phase 2 24, Phase 1/2 4, Phase 1 8) 2022: 64 trials (Observational 13, Not applicable 9, Phase 4 1, Phase 2/3 1, Phase 2 19, Phase 1/2 9, Phase 1 12) 2023: 58 trials (Observational 10, Not applicable 10, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 19, Phase 1/2 3, Phase 1 9) 2024: 92 trials (Observational 30, Not applicable 10, Phase 4 1, Phase 3 1, Phase 2/3 3, Phase 2 35, Phase 1 12) 2025: 59 trials (Observational 17, Not applicable 14, Phase 2 16, Phase 1/2 5, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 62
2025 59
2024 92
2023 58
2022 64
2021 60
2020 63
2019 45
2018 48
2017 45

Showing 10 of 26 earlier years.

Start your 14-day trial Email me all 26 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 75 trials starting in 2026 and about 65 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 166 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 367 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Cholangiocarcinoma trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 114
Phase 1/2 55
Phase 2 268
Phase 2/3 17
Phase 3 37
Phase 4 12
Not applicable 141
Observational 169
Expanded access 6

How many Cholangiocarcinoma trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 58
Recruiting 169
Enrolling by invitation 7
Active, not recruiting 57
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Cholangiocarcinoma trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 23

Which drugs are being tested for Cholangiocarcinoma? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 27
DURVALUMAB 26
"Capecitabine" 26
OXALIPLATIN 21
NAB paclitaxel 11

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 75
Cisplatin 1 56
Fluorouracile 16
Lenvatinib 1 15
Pemigatinib Pill 11

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Cholangiocarcinoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Sepsis 194 44
Pyrexia 171 30
Cholangitis 165 24
Abdominal pain 147 42
Vomiting 108 39

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Cholangiocarcinoma? (510)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma. Journal of hepatology 2026 Yes
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial. The lancet. Gastroenterology & hepatology 2026 Yes
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. The lancet. Gastroenterology & hepatology 2026 Yes
Survival Outcomes of Microwave Ablation Compared with Repeat Liver Resection in the Treatment of Recurrent Intrahepatic Cholangiocarcinoma. Radiology 2026 Yes
Locoregional Treatment Options for Locally Advanced Intrahepatic Cholangiocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2025 Yes

Showing 5 of 510 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (24)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Cholangiocarcinoma Annual incidence 1-9 / 100 000 United States US Exact
Cholangiocarcinoma Annual incidence 1-9 / 100 000 United States US Unspecified
Cholangiocarcinoma Annual incidence 1-9 / 100 000 United States US Exact
Cholangiocarcinoma Annual incidence 1-9 / 100 000 Japan Not stated Exact
Cholangiocarcinoma Annual incidence 1-9 / 100 000 Europe Not stated Exact

Showing 5 of 24 prevalence observations.

Start your 14-day trial Email me all 24 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Cholangiocarcinoma 70567 Exact Orphanet Rare Disease Ontology (ORDO)
Cholangiocarcinoma 70567 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages